Furthermore, mutations affecting the level of RUNX1 activity leading to loss of function, dominant negative gain of function, and/or overexpression are associated with other blood disorders such as familial platelet disorder with predisposition to acute myeloid leukemia and myelodysplastic syndrome, suggesting that the process of hematopoiesis is very sensitive to the level of RUNX1 activity [130–132]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.